Добірка наукової літератури з теми "End Stage Kidney Disease (ESKD)"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "End Stage Kidney Disease (ESKD)".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "End Stage Kidney Disease (ESKD)"
De La Mata, Nicole L., Philip Masson, Rustam Al-Shahi Salman, Patrick J. Kelly, and Angela C. Webster. "Death From Stroke in End-Stage Kidney Disease." Stroke 50, no. 2 (February 2019): 487–90. http://dx.doi.org/10.1161/strokeaha.118.023644.
Повний текст джерелаSaraf, Santosh L., Jesse Y. Hsu, Ana C. Ricardo, Rupal Mehta, Jing Chen, Teresa K. Chen, Michael J. Fischer, et al. "Anemia and Incident End-Stage Kidney Disease." Kidney360 1, no. 7 (May 20, 2020): 623–30. http://dx.doi.org/10.34067/kid.0000852020.
Повний текст джерелаReynolds, Meredith A., Kammi J. Henriksen, and Anthony Chang. "End-Stage Kidney Disease Is Overlooked as a Proximate Cause of Death at Autopsy." American Journal of Clinical Pathology 153, no. 6 (January 29, 2020): 772–75. http://dx.doi.org/10.1093/ajcp/aqz211.
Повний текст джерелаEllis, Robert J., Daniel P. Edey, Sharon J. Del Vecchio, Megan McStea, Scott B. Campbell, Carmel M. Hawley, David W. Johnson, et al. "End-Stage Kidney Disease following Surgical Management of Kidney Cancer." Clinical Journal of the American Society of Nephrology 13, no. 11 (September 28, 2018): 1641–48. http://dx.doi.org/10.2215/cjn.06560518.
Повний текст джерелаTanaka, Yuri, Nobuhiko Joki, and Hiroki Hase. "Ischemic Heart Disease in Patients with End-Stage Kidney Disease." Blood Purification 40, no. 4 (2015): 332–36. http://dx.doi.org/10.1159/000441582.
Повний текст джерелаTsuruya, Kazuhiko, Masahiro Eriguchi, Shunsuke Yamada, Hideki Hirakata, and Takanari Kitazono. "Cardiorenal Syndrome in End-Stage Kidney Disease." Blood Purification 40, no. 4 (2015): 337–43. http://dx.doi.org/10.1159/000441583.
Повний текст джерелаPalat, Gayatri, Srinivas Vinayak Shenoy, Lakshmitha Shetty, and Sivakumar Vishnubhotla. "Comprehensive Conservative Care in End-Stage Kidney Disease." Indian Journal of Palliative Care 27 (May 30, 2021): S11—S13. http://dx.doi.org/10.4103/ijpc.ijpc_63_21.
Повний текст джерелаLee, Gavin, and David W. Johnson. "Anticoagulation for Atrial Fibrillation in End-stage Kidney Disease." Journal of Controversies in Biomedical Research 1, no. 1 (October 29, 2015): 40–50. http://dx.doi.org/10.15586/jcbmr.2015.9.
Повний текст джерелаSprick, Justin D., Joe R. Nocera, Ihab Hajjar, W. Charles O’Neill, James Bailey, and Jeanie Park. "Cerebral blood flow regulation in end-stage kidney disease." American Journal of Physiology-Renal Physiology 319, no. 5 (November 1, 2020): F782—F791. http://dx.doi.org/10.1152/ajprenal.00438.2020.
Повний текст джерелаHsieh, Chia-Chen, Ming-Jen Chan, Yi-Jiun Su, Jen-Fen Fu, I.-Kuan Wang, Chao-Yu Chen, Cheng-Hao Weng, Wen-Hung Huang, Ching-Wei Hsu, and Tzung-Hai Yen. "Bone Marrow Hypocellularity in Patients with End-Stage Kidney Disease." Healthcare 9, no. 11 (October 27, 2021): 1452. http://dx.doi.org/10.3390/healthcare9111452.
Повний текст джерелаДисертації з теми "End Stage Kidney Disease (ESKD)"
Appiah, Boateng Edward. "Decision making in end stage kidney disease (ESKD) in Ghana : exploring patient and clinician perspectives." Thesis, University of Nottingham, 2016. http://eprints.nottingham.ac.uk/37965/.
Повний текст джерелаBlackwell, Kara. "The impermanence of reality : a grounded theory study of the experience of transition to palliative care for people with end-stage kidney disease (ESKD)." Thesis, University of Surrey, 2017. http://epubs.surrey.ac.uk/813806/.
Повний текст джерелаGregory, Deborah M. "Patients' perceptions of their experiences with end-stage renal disease (ESRD) and hemodialysis treatment." Thesis, National Library of Canada = Bibliothèque nationale du Canada, 1998. http://www.collectionscanada.ca/obj/s4/f2/dsk1/tape11/PQDD_0031/MQ47421.pdf.
Повний текст джерелаAlarcón, Parra Carla Patricia, Chachi Jesús Ángel Marcelo, and Salas Gabriela Judy Noa. "Implementación de un centro de hemodiálisis para pacientes con ERCT en el distrito de San Martín de Porres – Lima." Master's thesis, Universidad Peruana de Ciencias Aplicadas (UPC), 2021. http://hdl.handle.net/10757/657576.
Повний текст джерелаAt the beginning of 2020, 4,300 insured persons were registered with EsSalud diagnosed with Terminal Chronic Kidney Disease (ESRD) in the department of Lima, who have been receiving hemodialysis sessions at the National Renal Health Center (CNSR) and clinics hired for this service, as reported by the aforementioned IAFAS. On the part of those insured to the SIS, the Intangible Solidarity in Health Fund (FISSAL) reported that at the beginning of 2020, 6,268 insured have been receiving hemodialysis in private health centers in Metropolitan Lima and the different regions of the country. This project proposes to provide the outpatient hemodialysis service to patients with Terminal Chronic Kidney Disease affiliated to IAFAS EsSalud, since it has an over-demand for them that require the Hemodialysis service, and which is currently not covered even by its own offer nor by the one subcontracted to other hemodialysis centers. Our strategy is “Cost Leadership”, with a value proposition based on personalized attention with a multidisciplinary team, high quality standards and a patient-centered management model, according to the Terms of Reference (TOR) required by EsSalud. From a financial point of view, the total investment of the project is S /. 447,110.00 presenting a NPV of S /. 2,676,707.15 and an IRR is 86.1%. The main risks of the project are financial and economic, such as lack of liquidity and being hired by IAFAS EsSalud
Trabajo de investigación
Webster, Angela Claire. "Immunosuppression and malignancy in end stage kidney disease." University of Sydney, 2006. http://hdl.handle.net/2123/1186.
Повний текст джерелаIntroduction Kidney transplantation confers both survival and quality of life advantages over dialysis for most people with end-stage kidney disease (ESKD). The mortality rate on dialysis is 10-15% per year, compared with 2-4% per year post-transplantation. Short-term graft survival is related to control of the acute rejection process, requiring on-going immunosuppression. Most current immunosuppressive algorithms include one of the calcineurin inhibitors (CNI: cyclosporin or tacrolimus), an anti-metabolite (azathioprine or mycophenolate) and corticosteroids, with or without antibody induction agents (Ab) given briefly peri-transplantation. Despite this approach, between 15-35% of recipients undergo treatment for an episode of acute rejection (AR) within one year of transplantation. Transplantation is not without risk, and relative mortality rates for kidney recipients after the first post-transplant year remain 4-6 times that of the general population. Longer-term transplant and recipient survival are related to control of chronic allograft nephropathy (rooted in the interplay of AR, non-immunological factors, and the chronic nephrotoxicity of CNI) and limitation of the complications of chronic ESKD and long-term immunosuppression: cardiovascular disease, cancer and infection, which are responsible for 22%, 39% and 21% of deaths respectively. This thesis is presented as published works on the theme of immunosuppression and cancer after kidney transplantation. The work presented in the first chapters of this thesis has striven to identify, evaluate, synthesise and distil the entirety of evidence available of new and established immunosuppressive drug agents through systematic review of randomised trial data, with particular emphasis on quantifying harms of treatment. The final chapters use inception cohort data from the Australian and New Zealand Dialysis and Transplant Registry (ANZDATA), which is first validated then used to explore the risk of cancer in more detail than was possible from trial data alone. Interleukin 2 receptor antagonists Interleukin-2 receptor antagonists (IL2Ra, commercially available as basiliximab and daclizumab) are humanised or chimeric IgG monoclonal antibodies to the alpha subunit of the IL2 receptor present only on activated T lymphocytes, and the rationale for their use has been as induction agents peri-transplantation. Introduced in the mid-1990s, IL2Ra use has increased globally, and by 2003 38% of new kidney transplant recipients in the United States and 25% in Australasia received an IL2Ra. This study aimed to systematically identify and synthesise the evidence of effects of IL2Ra as an addition to standard therapy, or as an alternative to other induction agents. We identified 117 reports from 38 randomised trials involving 4893 participants. Where IL2Ra were compared with placebo (17 trials; 2786 patients), graft loss was not different at one (Relative Risk -RR 0.84; 0.64 to 1.10) or 3 years (RR 1.08; 0.71 to1.64). AR was reduced at 6 months (RR 0.66; 0.59 to 0.74) and at 1 year (RR 0.66; 0.59 to 0.74) but cytomegalovirus (CMV) disease (RR 0.82; CI 0.65 to 1.03) and malignancy (RR 0.67; 0.33 to1.36) were not different. Where IL2Ra were compared with other antibody therapy no significant differences in treatment effects were demonstrated, but IL2Ra had significantly fewer side effects. Given a 40% risk of rejection, 7 patients would need treatment with IL2Ra in addition to standard therapy, to prevent 1 patient having rejection, with no definite improvement in graft or patient survival. There was no apparent difference between basiliximab and daclizumab. Tacrolimus versus cyclosporin for primary immunosuppression There are pronounced global differences in CNI use; 63% of new kidney transplant recipients in the USA but only 22% in Australia receive tacrolimus as part of the initial immunosuppressive regimen. The side effects of CNI differ: tacrolimus is associated more with diabetes and neurotoxicity, but less with hypertension and dyslipidaemia than cyclosporin, with uncertainty about equivalence of nephrotoxicity or how these relate to patient and graft survival, or impact on patient compliance and quality of life. This study aimed to systematically review and synthesise the positive and negative effects of tacrolimus and cyclosporin as initial therapy for renal transplant recipients. We identified 123 reports from 30 randomised trials involving 4102 participants. At 6 months graft loss was reduced in tacrolimus-treated recipients (RR 0•56; 0•36 to 0•86), and this effect persisted for 3 years. The relative reduction in graft loss with tacrolimus diminished with higher levels of tacrolimus (P=0.04), but did not vary with cyclosporin formulation (P=0.97) or cyclosporin level (P=0.38). At 1 year, tacrolimus patients suffered less AR (RR 0•69; 0•60 to 0•79), and less steroid-resistant AR (RR 0•49; 0•37 to 0•64), but more insulin-requiring diabetes (RR 1•86; 1•11 to 3•09), tremor, headache, diarrhoea, dyspepsia and vomiting. The relative excess in diabetes increased with higher levels of tacrolimus (P=0.003). Cyclosporin-treated recipients experienced significantly more constipation and cosmetic side-effects. We demonstrated no differences in infection or malignancy. Treating 100 recipients with tacrolimus instead of cyclosporin for the 1st year post-transplantation avoids 12 suffering acute rejection and 2 losing their graft but causes an extra 5 to become insulin dependent diabetics, thus optimal drug choice may vary among patients. Target of rapamycin inhibitors for primary immunosuppression Target of rapamycin inhibitors (TOR-I) are among the newest immunosuppressive agents and have a novel mode of action but uncertain clinical role. Sirolimus is a macrocyclic lactone antibiotic and everolimus is a derivative of sirolimus. Both prevent DNA synthesis resulting in arrest of the cell cycle. Animal models suggested TOR-I would provide synergistic immunosuppression when combined with CNI, but early clinical studies demonstrated synergistic nephrotoxicity. Since then diverse trials have explored strategies that avoid this interaction and investigated other potential benefits. The aim of this study was to systematically identify and synthesise available evidence of sirolimus and everolimus when used in initial immunosuppressive regimens for kidney recipients. We identified 142 reports from 33 randomised trials involving 7114 participants, with TOR-I evaluated in four different primary immunosuppressive algorithms: as replacement for CNI, as replacement for antimetabolites, in combination with CNI at low and high dose, and with variable dose of CNI. When TOR-I replaced CNI (8 trials, 750 participants), there was no difference in AR (RR 1.03; 0.74 to 1.44), but creatinine was lower (WMD -18.31 umol/l; -30.96 to -5.67), and bone marrow more suppressed (leucopoenia RR 2.02; 1.12 to 3.66, thrombocytopenia RR 6.97; 2.97 to 16.36, anaemia RR 1.67; 1.27 to 2.20). When TOR-I replaced antimetabolites (11 trials, 3966 participants), AR and CMV were reduced (RR 0.84; 0.71 to 0.99 and RR 0.49; 0.37 to 0.65) but hypercholesterolaemia was increased (RR 1.65; 1.32 to 2.06). When low was compared to high-dose TOR-I, with equal CNI dose (10 trials, 3175 participants), AR was increased (RR 1.23; 1.06 to 1.43) but GFR higher (WMD 4.27 ml/min; 1.12 to 7.41). When low-dose TOR-I and standard-dose CNI were compared to higher-dose TOR-I and reduced CNI AR was reduced (RR 0.67; 0.52 to 0.88), but GFR also reduced (WMD -9.46 ml/min; -12.16 to -6.76). There was no significant difference in mortality, graft loss or malignancy risk demonstrated for TOR-I in any comparison. Generally surrogate endpoints for graft survival favoured TOR-I (lower risk of acute rejection and higher GFR) and surrogate endpoints for patient outcomes were worsened by TOR-I (bone marrow suppression, lipid disturbance). Long-term hard-endpoint data from methodologically robust randomised trials are still needed. Monoclonal and polyclonal antibody therapy for treating acute rejection Strategies for treating AR include pulsed steroids, an antibody (Ab) preparation, the alteration of background immunosuppression, or combinations of these options. In 2002, in the USA 61.4% of patients with AR received steroids, 20.4% received Ab and 18.2% received both. The Ab available for AR are not new: horse and rabbit derived polyclonal antibodies (ATG and ALG) have been used for 35 years, and a mouse monoclonal antibody (muromonab-CD3) became available in the late 1980s. These preparations remove the functional T-cell population from circulation, producing powerful saturation immunosuppression which is useful for AR but which may be complicated by immediate toxicity and higher rates of infection and malignancy. The aim of this study was to systematically evaluate and synthesise all evidence available to clinicians for treating AR in kidney recipients. We identified 49 reports from 21 randomised trials involving 1394 participants. Outcome measures were inconsistent and incompletely defined across trials. Fourteen trials (965 patients) compared therapies for 1st AR episodes (8 Ab versus steroid, 2 Ab versus another Ab, 4 other comparisons). In treating first rejection, Ab was better than steroid in reversing AR (RR 0.57; CI 0.38 to 0.87) and preventing graft loss (RR 0.74; CI 0.58 to 0.95) but there was no difference in preventing subsequent rejection (RR 0.67; CI 0.43 to 1.04) or death (RR 1.16; CI 0.57 to 2.33) at 1 year. Seven trials (422 patients) investigated Ab treatment of steroid-resistant rejection (4 Ab vs another Ab, 1 different doses Ab, 1 different formulation Ab, 2 other comparisons). There was no benefit of muromonab-CD3 over ATG or ALG in reversing rejection (RR 1.32; CI 0.33 to 5.28), preventing subsequent rejection (RR 0.99; CI 0.61 to 1.59), graft loss (RR 1.80; CI 0.29 to 11.23) or death (RR 0.39; CI 0.09 to 1.65). Given the clinical problem caused by AR, comparable data are sparse, and clinically important differences in outcomes between widely used interventions have not been excluded. Standardised reproducible outcome criteria are needed. Validity of cancer data in an end stage kidney disease registry Registries vary in whether the data they collect are given voluntarily or as a requirement of law, the completeness of population coverage, the breadth of data collected and whether data are assembled directly or indirectly through linkage to other databases. Data quality is crucial but difficult to measure objectively. Formal audit of ANZDATA cancer records has not previously taken place. The aim of this study was to assess agreement of records of incident cancer diagnoses held in ANZDATA (voluntary reporting system) with those reported under statute to the New South Wales (NSW) state Central Cancer Registry (CCR), to explore the strengths and weaknesses of both reporting systems, and to measure the impact of any disagreement on results of cancer analyses. From 1980-2001, 9453 residents received dialysis or transplantation in NSW. Records from ANZDATA registrants were linked to CCR using probabilistic matching and agreement between registries for patients with 1 or more cancers, all cancers and site-specific cancer was estimated using the kappa-statistic (κ). ANZDATA recorded 867 cancers in 779 (8.2%) registrants; CCR 867 cancers in 788 (8.3%), with κ =0.76. ANZDATA had sensitivity 77.3% (CI 74.2 to 80.2), specificity 98.1% (CI 97.7 to 98.3) if CCR records were regarded as the reference standard. Agreement was similar for diagnoses whilst receiving dialysis (κ =0.78) or after transplantation (κ =0.79), but varied by cancer type. Melanoma (κ =0.61) and myeloma (κ =0.47) were less good; lymphoma (κ =0.80), leukaemia (κ =0.86) and breast cancer (κ =0.85) were very good. Artefact accounted for 20.8% non-concordance but error and misclassification did occur in both registries. Cancer risk did not differ in any important way whether estimated using ANZDATA or CCR records. Quality of cancer records in ANZDATA are high, differences largely explicable, and seem unlikely to alter results of analyses. Risk of cancer after kidney transplantation Existing data on the magnitude of excess risk of cancer across different kidney recipient groups are sparse. Quantifying an individual transplant candidate’s cancer risk informs both pre-transplant counselling, treatment decisions and has implications for monitoring, screening and follow-up after transplantation. The aims of this study were firstly to establish the risk of cancer in the post-transplant population compared to that experienced by the general population, and secondly to quantify how excess risk varied within the transplanted population, seeking to establish meaningful absolute risk estimates for post-transplant cancer based on unalterable recipient characteristics known a priori at the time of transplantation. 15,183 residents of Australia and New Zealand had a transplant between 1963 and 2004, and were followed for a median of 7.2 years (130,186 person-years), with 1642 (10.8%) developing cancer. Overall, kidney recipients had 3 times the cancer risk, with risk inversely related to age (Standardised Incidence Ratio of 15 to 30 in children reducing to 2 in people > 65 years). Female recipients aged 25 -29 had rates of cancer (779.2/100,000) equivalent to women aged 55 - 59 from the general population. The risk pattern of lymphoma, colorectal and breast cancer was similar to the overall age trend, melanoma showed less variability across ages and prostate cancer showed no risk increase. Within the transplanted population cancer risk was affected by age differently for each sex (P=0.007), and was elevated for recipients with prior non-skin malignancy (Hazard Ratio: HR 1.40; 1.03 to 1.89), of white race (HR 1.36; 1.12 to 1.89), but reduced for those with diabetic ESKD (HR 0.67; 0.50 to 0.89) Rates of cancer in kidney recipients were similar to non-transplanted people 20 -30 years older, but risk differed across patient groups. Men aged 45 - 54 at transplantation with graft function at 10 years had a risk of cancer that varied from 1 in 13 (non-white, diabetic ESKD, no prior cancer) to 1 in 5 (white, prior cancer, ESKD from other causes).
Webster, Angela C. "Immunosuppression and malignancy in end stage kidney disease." Connect to full text, 2006. http://hdl.handle.net/2123/1186.
Повний текст джерелаTitle from title screen (viewed 21 May 2007). Submitted in fulfilment of the requirements for the degree of Doctor of Philosophy to the School of Public Health, Faculty of Medicine. Includes bibliographical references. Also available in print form.
Metcalfe, Wendy. "End stage renal disease : outcomes and standards of care." Thesis, University of Aberdeen, 2002. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.251850.
Повний текст джерелаJassal, Sarbjit Vanita. "Kidney transplantation in elderly patients with end-stage renal disease." Thesis, National Library of Canada = Bibliothèque nationale du Canada, 1998. http://www.collectionscanada.ca/obj/s4/f2/dsk1/tape11/PQDD_0005/MQ40712.pdf.
Повний текст джерелаNicholas, Pauline. "Impaired cognition in end stage kidney disease: Prevalence, predictors and differences between treatment." Thesis, Queensland University of Technology, 2020. https://eprints.qut.edu.au/203098/1/Pauline_Nicholas_Thesis.pdf.
Повний текст джерелаAlashek, Wiam Abdulaziz. "Epidemiology of dialysis-treated end-stage kidney disease in adults in Libya." Thesis, University of Nottingham, 2013. http://eprints.nottingham.ac.uk/28388/.
Повний текст джерелаКниги з теми "End Stage Kidney Disease (ESKD)"
Friedman, Eli A. Present and future therapies for end-stage renal disease. New Jersey: World Scientific, 2010.
Знайти повний текст джерелаJassal, Sarbjit Vanita. Kidney transplantation in elderly patients with end-stage renal disease. Ottawa: National Library of Canada, 1998.
Знайти повний текст джерелаUnited States. Agency for Health Care and Policy Research. Laboratory tests in end-stage renal disease patients undergoing dialysis. Rockville, Md: U.S. Dept. of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research, 1994.
Знайти повний текст джерелаGreen, Ira. Laboratory tests in end-stage renal disease patients undergoing dialysis. Rockville, Md: U.S. Dept. of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research, 1994.
Знайти повний текст джерелаGreen, Ira. Laboratory tests in end-stage renal disease patients undergoing dialysis. Rockville, Md: U.S. Dept. of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research, 1994.
Знайти повний текст джерелаGreen, Ira. Laboratory tests in end-stage renal disease patients undergoing dialysis. Rockville, Md: U.S. Dept. of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research, 1994.
Знайти повний текст джерелаGreen, Ira. Laboratory tests in end-stage renal disease patients undergoing dialysis. Rockville, Md: U.S. Dept. of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research, 1994.
Знайти повний текст джерелаFlorida. Legislature. House of Representatives. Committee on Health Regulation. Overview of kidney dialysis studies and providers of end stage renal disease care. [Tallahassee, Fla.]: The Committee, 2001.
Знайти повний текст джерелаHalper, Thomas. The misfortunes of others: End-stage renal disease in the United Kingdom. Cambridge: Cambridge University Press, 1989.
Знайти повний текст джерела1938-, Hardy Mark A., ed. Psychosocial aspects of end-stage renal disease: Issues of our times. New York: Haworth Press, 1991.
Знайти повний текст джерелаЧастини книг з теми "End Stage Kidney Disease (ESKD)"
Lantos, John D. "Ethical Issues in End Stage Kidney Disease (ESKD)." In Pediatric Kidney Disease, 1625–33. Berlin, Heidelberg: Springer Berlin Heidelberg, 2016. http://dx.doi.org/10.1007/978-3-662-52972-0_61.
Повний текст джерелаPandey, Soumya, and Terry Harville. "Kidney Transplantation in a Patient with End Stage Renal Disease (ESRD) Secondary to Focal Segmental Glomerulosclerosis." In Pediatric Autoimmunity and Transplantation, 325–28. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-26280-8_56.
Повний текст джерелаMartinusen, Dan. "Chronic Kidney Disease and End Stage Renal Disease." In Renal Medicine and Clinical Pharmacy, 45–115. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-37655-0_4.
Повний текст джерелаGhosn, Muriel, and Fuad N. Ziyadeh. "Treatment of the Patient with End-Stage Diabetic Nephropathy." In Diabetes and Kidney Disease, 215–31. Oxford, UK: Wiley-Blackwell, 2012. http://dx.doi.org/10.1002/9781118494073.ch16.
Повний текст джерелаAl Khunaizi, Ahd, and Ahsan Alam. "End-Stage Renal Disease in Patients with Autosomal Dominant Polycystic Kidney Disease." In Polycystic Kidney Disease, 229–41. New York, NY: Springer New York, 2018. http://dx.doi.org/10.1007/978-1-4939-7784-0_14.
Повний текст джерелаSchaefer, Franz. "Hypertension in End-Stage Kidney Disease: Dialysis." In Pediatric Hypertension, 499–513. Cham: Springer International Publishing, 2023. http://dx.doi.org/10.1007/978-3-031-06231-5_48.
Повний текст джерелаSeeman, Tomáš. "Hypertension in End-Stage Kidney Disease: Transplantation." In Pediatric Hypertension, 515–32. Cham: Springer International Publishing, 2023. http://dx.doi.org/10.1007/978-3-031-06231-5_49.
Повний текст джерелаSchaefer, Franz. "Hypertension in End-Stage Kidney Disease: Dialysis." In Pediatric Hypertension, 1–15. Cham: Springer International Publishing, 2023. http://dx.doi.org/10.1007/978-3-319-31420-4_48-3.
Повний текст джерелаSeeman, Tomáš. "Hypertension in End-Stage Kidney Disease: Transplantation." In Pediatric Hypertension, 1–19. Cham: Springer International Publishing, 2023. http://dx.doi.org/10.1007/978-3-319-31420-4_49-3.
Повний текст джерелаCantarin, Maria Paula Martinez, and Jerry McCauley. "Epidemiology of End-Stage Renal Disease and Kidney Transplantation." In Contemporary Kidney Transplantation, 1–7. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-14779-6_24-1.
Повний текст джерелаТези доповідей конференцій з теми "End Stage Kidney Disease (ESKD)"
Boukhechba, Mehdi, Mingyue Tang, Brendan Bowman, Jamie Zoellner, and Emaad Abdel-Rahman. "A Smartwatch Based system for Monitoring Fluid Consumption of End Stage Kidney Patients." In 13th International Conference on Applied Human Factors and Ergonomics (AHFE 2022). AHFE International, 2022. http://dx.doi.org/10.54941/ahfe1002101.
Повний текст джерелаDillon, James, Eoin Bergin, Shodan Osman, and Syed Ali Aown. "P86 Idiopathic interstitial nephritis (IN) leading to end stage kidney disease (ESKD) in a 17-year-old male." In Faculty of Paediatrics of the Royal College of Physicians of Ireland, 9th Europaediatrics Congress, 13–15 June, Dublin, Ireland 2019. BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health, 2019. http://dx.doi.org/10.1136/archdischild-2019-epa.441.
Повний текст джерелаMatthews, Michael, Joanne Reid, Clare McKeaveney, and Helen Noble. "19 Knowledge requirements and unmet needs of informal caregivers of patients with end-stage kidney disease (ESKD) receiving haemodialysis." In The Marie Curie Research Conference Improving End of Life for All Sunday 30 January – Friday 4 February 2022. British Medical Journal Publishing Group, 2022. http://dx.doi.org/10.1136/spcare-2021-mcrc.19.
Повний текст джерелаAbohtyra, Rammah M., and Y. Chait. "New Algorithm to Design Real Time Optimal and Robust Ultrafiltration Rates in Chronic Kidney Disease to Prevent Cardiovascular Morbidity and Mortality." In ASME 2018 Dynamic Systems and Control Conference. American Society of Mechanical Engineers, 2018. http://dx.doi.org/10.1115/dscc2018-9172.
Повний текст джерелаHuang, Zhongping, Jie Ren, and Anilchandra Attaluri. "Experimental Study of a Hybrid Renal Replacement System." In ASME 2013 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2013. http://dx.doi.org/10.1115/sbc2013-14326.
Повний текст джерелаAbohtyra, Rammah M., C. V. Hollot, J. Horowitz, M. G. Germain, and Y. Chait. "Designing Robust Ultrafiltration Rate Profiles Based on Identifying Fluid Volume Model Parameters During Hemodialysis." In ASME 2017 Dynamic Systems and Control Conference. American Society of Mechanical Engineers, 2017. http://dx.doi.org/10.1115/dscc2017-5341.
Повний текст джерелаSmith, Robert E., Nicole C. Docherty, P. Alex Smith, Duncan J. Maitland, and Alan C. Glowczwski. "A Vascular Access Port for Dialysis With a Polyurethane Foam Seal: A Pilot Study." In 2017 Design of Medical Devices Conference. American Society of Mechanical Engineers, 2017. http://dx.doi.org/10.1115/dmd2017-3318.
Повний текст джерелаBroderick, Stephen P., Gráinne Carroll, and Micheal Walsh. "Geometric Enhancements of an Arteriovenous Graft." In ASME 2009 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2009. http://dx.doi.org/10.1115/sbc2009-206863.
Повний текст джерелаMcNally, Andrew, A. George Akingba, and Philippe Sucosky. "Computational Hemodynamic Assessment of a Novel Modular Anastomotic Valve Device for Improving Hemodialysis Vascular Access Patency." In ASME 2013 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2013. http://dx.doi.org/10.1115/sbc2013-14560.
Повний текст джерелаHo, Samuel Chung-sum, Eugene Yu-hin Chan, Ellen Yu, Matthew Hon-lam Lee, Yuet-ling Tung, and Alison Lap-tak Ma. "335 Fracture burden in paediatric end stage kidney disease." In RCPCH Conference Singapore. BMJ Publishing Group Ltd, 2021. http://dx.doi.org/10.1136/bmjpo-2021-rcpch.185.
Повний текст джерелаЗвіти організацій з теми "End Stage Kidney Disease (ESKD)"
Wala, Kamila, and Jacek Szepietowski. Difelikefalin in the treatment of chronic kidney disease-associated pruritus: a systematic review. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, May 2022. http://dx.doi.org/10.37766/inplasy2022.5.0154.
Повний текст джерела